ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

Abstract Number: 0942

G Protein-coupled Receptor Kinase 5 in Fibrotic Tissue Remodeling
Abstract Number: 2247

Gender Differences in Switching Biological and Targeted Synthetic Therapies in Psoriatic Arthritis
Abstract Number: 2217

Gender Disparities in Disease Activity Scores and Treatment Response Among Patients with Axial Spondyloarthritis
Abstract Number: 0170

Gender Equity Amongst Rheumatology Professionals: Preliminary Findings of the Coalition for Health and Gender Equity E-survey (CHANGE Group)
Abstract Number: 2450

Gene by Respiratory Disease Interactions Associated with Developing Rheumatoid Arthritis
Abstract Number: 1146

Gene X Environment Paradigm: Exemplified by Selected Cases of Autoinflammatory Diseases
Abstract Number: 2016

Generation of a Human 3D in Vitro Bone Model That Mimics Glucocorticoid-induced Osteoporosis
Abstract Number: 1710

Genetic Associations in Juvenile Idiopathic Arthritis Determined with an Electronic Health Record Based Approach
Abstract Number: 0560

Genetic Determinants of Lupus Nephritis and Kidney Function in Systemic Lupus Erythematosus
Abstract Number: 0015

Genetic Predisposition to a Positive Antinuclear Antibody Test Is Not Associated with Increased Risk of Disease
Abstract Number: 2115

Genetic Risk Load as a Predictor of Radiographic Damage and Mortality in Female Patients with Rheumatoid Arthritis
Abstract Number: 0930

Genetic Risk Profiles of Patients with Lupus Nephritis to Identify Those at Risk for Kidney Deterioration and Eventual Damage
Abstract Number: 1109

Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis
Abstract Number: 0034

Genome-Wide Association Study for Loci Associated with Positive Antinuclear Antibodies in a Large Hospital Biobank
Abstract Number: 1616

Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies
Abstract Number: 1031

Geographic Socioeconomic Influences on Disease Activity in Rheumatoid Arthritis in an Academic and Safety-Net Hospital System
Abstract Number: 1817

Geographic Variability of Inflammatory Bowel Disease Related Mortality, 1999-2019; CDC WONDER
Abstract Number: 2415

Giant Cell Arteritis Is Associated with Worse Hospital Outcomes in Aortic Aneurysm/Dissection Hospitalizations: A Nationwide United States Population-Based Study
Abstract Number: 0733

Global Identification of Lupus Genetic Risk Variants Facilitating the Type I Interferon Pathway Through CRISPR-based Genomic Screening
Abstract Number: 0715

Glucocorticoid Toxicity in Patients with IgG4-Related Disease Within the First Year of Treatment
Abstract Number: 2141

Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR)
Abstract Number: 0447

Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER
Abstract Number: 1446

Glucocorticoids Use Is a Major Driver of Self-perceived Depression in Systemic Lupus Erythematosus: Insights from a Large, Prospective and Multicenter Study Using RELESSERPROS Register’s Database
Abstract Number: 0059

GM-CSF by Natural Killer Cells Drives Inflammatory Arthritis in HIV-Infected Humanized Mice
Abstract Number: 0057

GM-CSF receptor/SYK/JNK/FOXO1/CD11c Signaling Enhances Cell Migration to Promote Atherosclerosis
Abstract Number: 2032

Goal Concordance in Rheumatoid Arthritis Patients with Depression – What Do Patients Prioritize?
Abstract Number: 1202

Goal Concordant Patient-clinician Dyads Have Higher Odds of Communication Around Rheumatoid Arthritis Goals
Abstract Number: 1793

Goblet Cell Specific Anti-Apoptotic Role of Interleukin-24 in Spondyloarthritis-Associated Ileitis
Abstract Number: 0241

Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness Trial
Abstract Number: 0240

Gout: A Gateway to Chronic Opioid Use?
Abstract Number: 0094

Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
Abstract Number: 0955

GRB2 Serves as a Viable Target Against Skin Fibrosis in Systemic Sclerosis by Regulating Endothelial Cell Apoptosis
Abstract Number: 2241

Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Abstract Number: 1428

Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
Abstract Number: 2236

Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis
Abstract Number: 2232

Guselkumab, an IL-23p19 Subunit–specific Monoclonal Antibody, Is Able to Bind CD64+ Myeloid Cells, Potently Neutralize IL-23 Produced from the Cells, and Mediate Internalization of IL-23
Abstract Number: 2584

Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis
Abstract Number: 1774

Gut Microbiota and Permeability Biomarkers for Diagnosis and Prognosis in Rheumatoid Arthritis Associated Interstitial Lung Disease
Abstract Number: 1730

Gut Microbiota Dysbiosis Impact Autonomic Function in Rheumatoid Arthritis Patients

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].